https://bi2536inhibitor.com/sy....stematic-assessment-
The patients were stratified into two cohorts: RARP with ePLND (ePLND group) and NCHT plus RARP without ePLND (NCHT group). The complication rates (based on the Clavien-Dindo grading system), biochemical recurrence-free periods, and times until the emergence of castration-resistant prostate cancer (CRPC) were contrasted between the treatment groups. We performed a multivariable Cox regression analysis, utilizing inverse probability weighting (IPT
כמו
תגובה
לַחֲלוֹק
